Profund Advisors LLC Grows Position in DexCom, Inc. (NASDAQ:DXCM)

Profund Advisors LLC raised its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 6.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 23,359 shares of the medical device company’s stock after purchasing an additional 1,317 shares during the quarter. Profund Advisors LLC’s holdings in DexCom were worth $3,002,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Personal CFO Solutions LLC lifted its holdings in shares of DexCom by 3.4% in the second quarter. Personal CFO Solutions LLC now owns 2,964 shares of the medical device company’s stock worth $381,000 after buying an additional 98 shares in the last quarter. Commonwealth Equity Services LLC lifted its holdings in shares of DexCom by 22.4% in the second quarter. Commonwealth Equity Services LLC now owns 43,134 shares of the medical device company’s stock worth $5,543,000 after buying an additional 7,905 shares in the last quarter. Shelton Capital Management lifted its holdings in shares of DexCom by 4.0% in the second quarter. Shelton Capital Management now owns 34,177 shares of the medical device company’s stock worth $4,392,000 after buying an additional 1,329 shares in the last quarter. Cary Street Partners Investment Advisory LLC lifted its holdings in shares of DexCom by 40.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 1,038 shares of the medical device company’s stock worth $133,000 after buying an additional 300 shares in the last quarter. Finally, Artisan Partners Limited Partnership increased its position in shares of DexCom by 22.0% in the second quarter. Artisan Partners Limited Partnership now owns 2,426,385 shares of the medical device company’s stock worth $311,815,000 after purchasing an additional 436,852 shares during the last quarter. 93.88% of the stock is owned by hedge funds and other institutional investors.

DexCom Price Performance

NASDAQ DXCM opened at $104.97 on Monday. DexCom, Inc. has a one year low of $74.75 and a one year high of $139.55. The stock has a 50-day moving average of $91.03 and a 200 day moving average of $109.77. The company has a market capitalization of $40.56 billion, a price-to-earnings ratio of 115.35, a PEG ratio of 2.13 and a beta of 1.13. The company has a debt-to-equity ratio of 1.07, a quick ratio of 2.50 and a current ratio of 2.80.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 26th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.34 by $0.16. The business had revenue of $975.00 million during the quarter, compared to the consensus estimate of $939.64 million. DexCom had a return on equity of 25.05% and a net margin of 11.08%. The business’s quarterly revenue was up 26.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.28 EPS. On average, sell-side analysts forecast that DexCom, Inc. will post 1.43 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently weighed in on DXCM shares. Barclays upped their price objective on shares of DexCom from $115.00 to $138.00 and gave the stock an “equal weight” rating in a research report on Monday, July 31st. Stifel Nicolaus cut their target price on shares of DexCom from $155.00 to $145.00 and set a “buy” rating on the stock in a report on Tuesday, October 10th. UBS Group cut their target price on shares of DexCom from $175.00 to $138.00 and set a “buy” rating on the stock in a report on Wednesday, September 6th. SVB Leerink started coverage on DexCom in a research report on Monday, October 16th. They set an “outperform” rating and a $110.00 price objective for the company. Finally, Robert W. Baird lowered their price objective on DexCom from $153.00 to $130.00 and set an “outperform” rating for the company in a research report on Monday, August 21st. Three analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $130.93.

Insider Activity at DexCom

In related news, CFO Jereme M. Sylvain sold 1,844 shares of the business’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $104.38, for a total value of $192,476.72. Following the transaction, the chief financial officer now directly owns 72,867 shares of the company’s stock, valued at approximately $7,605,857.46. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CFO Jereme M. Sylvain sold 1,844 shares of the company’s stock in a transaction that occurred on Tuesday, August 22nd. The stock was sold at an average price of $104.38, for a total transaction of $192,476.72. Following the sale, the chief financial officer now directly owns 72,867 shares of the company’s stock, valued at approximately $7,605,857.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Steven Robert Pacelli sold 411 shares of the business’s stock in a transaction that occurred on Wednesday, August 23rd. The shares were sold at an average price of $107.03, for a total value of $43,989.33. Following the transaction, the director now directly owns 126,008 shares in the company, valued at approximately $13,486,636.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,752 shares of company stock worth $850,297. 0.41% of the stock is owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.